Biotechnology & Pharmaceutical Services Outsourcing Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030

Table of Contents

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Biotechnology & Pharmaceutical Services Outsourcing Market, By End Use

7.1. Biotechnology & Pharmaceutical Services Outsourcing Market, by End Use Type, 2021-2030

7.1.1. Pharma Companies

7.1.1.1. Market Revenue and Forecast (2017-2030)

7.1.2. Biotech Companies

7.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 8. Global Biotechnology & Pharmaceutical Services Outsourcing Market, By Service

8.1. Biotechnology & Pharmaceutical Services Outsourcing Market, by Service, 2021-2030

8.1.1. Consulting

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Auditing & Assessment

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Regulatory Affairs

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Product Maintenance

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. Product Design & Development

8.1.5.1. Market Revenue and Forecast (2017-2030)

8.1.6. Product Testing & Validation

8.1.6.1. Market Revenue and Forecast (2017-2030)

8.1.7. Training & Education

8.1.7.1. Market Revenue and Forecast (2017-2030)

8.1.8. Others

8.1.8.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Biotechnology & Pharmaceutical Services Outsourcing Market, Regional Estimates and Trend Forecast

9.1. North America

9.1.1. Market Revenue and Forecast, by End Use (2017-2030)

9.1.2. Market Revenue and Forecast, by Service (2017-2030)

9.1.3. U.S.

9.1.3.1. Market Revenue and Forecast, by End Use (2017-2030)

9.1.3.2. Market Revenue and Forecast, by Service (2017-2030)

9.1.4. Rest of North America

9.1.4.1. Market Revenue and Forecast, by End Use (2017-2030)

9.1.4.2. Market Revenue and Forecast, by Service (2017-2030)

9.2. Europe

9.2.1. Market Revenue and Forecast, by End Use (2017-2030)

9.2.2. Market Revenue and Forecast, by Service (2017-2030)

9.2.3. UK

9.2.3.1. Market Revenue and Forecast, by End Use (2017-2030)

9.2.3.2. Market Revenue and Forecast, by Service (2017-2030)

9.2.4. Germany

9.2.4.1. Market Revenue and Forecast, by End Use (2017-2030)

9.2.4.2. Market Revenue and Forecast, by Service (2017-2030)

9.2.5. France

9.2.5.1. Market Revenue and Forecast, by End Use (2017-2030)

9.2.5.2. Market Revenue and Forecast, by Service (2017-2030)

9.2.6. Rest of Europe

9.2.6.1. Market Revenue and Forecast, by End Use (2017-2030)

9.2.6.2. Market Revenue and Forecast, by Service (2017-2030)

9.3. APAC

9.3.1. Market Revenue and Forecast, by End Use (2017-2030)

9.3.2. Market Revenue and Forecast, by Service (2017-2030)

9.3.3. India

9.3.3.1. Market Revenue and Forecast, by End Use (2017-2030)

9.3.3.2. Market Revenue and Forecast, by Service (2017-2030)

9.3.4. China

9.3.4.1. Market Revenue and Forecast, by End Use (2017-2030)

9.3.4.2. Market Revenue and Forecast, by Service (2017-2030)

9.3.5. Japan

9.3.5.1. Market Revenue and Forecast, by End Use (2017-2030)

9.3.5.2. Market Revenue and Forecast, by Service (2017-2030)

9.3.6. Rest of APAC

9.3.6.1. Market Revenue and Forecast, by End Use (2017-2030)

9.3.6.2. Market Revenue and Forecast, by Service (2017-2030)

9.4. MEA

9.4.1. Market Revenue and Forecast, by End Use (2017-2030)

9.4.2. Market Revenue and Forecast, by Service (2017-2030)

9.4.3. GCC

9.4.3.1. Market Revenue and Forecast, by End Use (2017-2030)

9.4.3.2. Market Revenue and Forecast, by Service (2017-2030)

9.4.4. North Africa

9.4.4.1. Market Revenue and Forecast, by End Use (2017-2030)

9.4.4.2. Market Revenue and Forecast, by Service (2017-2030)

9.4.5. South Africa

9.4.5.1. Market Revenue and Forecast, by End Use (2017-2030)

9.4.5.2. Market Revenue and Forecast, by Service (2017-2030)

9.4.6. Rest of MEA

9.4.6.1. Market Revenue and Forecast, by End Use (2017-2030)

9.4.6.2. Market Revenue and Forecast, by Service (2017-2030)

9.5. Latin America

9.5.1. Market Revenue and Forecast, by End Use (2017-2030)

9.5.2. Market Revenue and Forecast, by Service (2017-2030)

9.5.3. Brazil

9.5.3.1. Market Revenue and Forecast, by End Use (2017-2030)

9.5.3.2. Market Revenue and Forecast, by Service (2017-2030)

9.5.4. Rest of LATAM

9.5.4.1. Market Revenue and Forecast, by End Use (2017-2030)

9.5.4.2. Market Revenue and Forecast, by Service (2017-2030)

Chapter 10. Company Profiles

10.1. The Quantic Group

10.1.1. Company Overview

10.1.2. Product Offerings

10.1.3. Financial Performance

10.1.4. Recent Initiatives

10.2. IQVIA

10.2.1. Company Overview

10.2.2. Product Offerings

10.2.3. Financial Performance

10.2.4. Recent Initiatives

10.3. Parexel International Corporation

10.3.1. Company Overview

10.3.2. Product Offerings

10.3.3. Financial Performance

10.3.4. Recent Initiatives

10.4. Lachman Consultant Services, Inc.

10.4.1. Company Overview

10.4.2. Product Offerings

10.4.3. Financial Performance

10.4.4. Recent Initiatives

10.5. GMP Pharmaceuticals Pty Ltd.

10.5.1. Company Overview

10.5.2. Product Offerings

10.5.3. Financial Performance

10.5.4. Recent Initiatives

10.6. Concept Heidelberg GmbH

10.6.1. Company Overview

10.6.2. Product Offerings

10.6.3. Financial Performance

10.6.4. Recent Initiatives

10.7. Covance Inc.

10.7.1. Company Overview

10.7.2. Product Offerings

10.7.3. Financial Performance

10.7.4. Recent Initiatives

10.8. Charles River Laboratories

10.8.1. Company Overview

10.8.2. Product Offerings

10.8.3. Financial Performance

10.8.4. Recent Initiatives

10.9. PRA Health Sciences

10.9.1. Company Overview

10.9.2. Product Offerings

10.9.3. Financial Performance

10.9.4. Recent Initiatives

10.10. ICON plc

10.10.1. Company Overview

10.10.2. Product Offerings

10.10.3. Financial Performance

10.10.4. Recent Initiatives

Chapter 11. Research Methodology

11.1. Primary Research

11.2. Secondary Research

11.3. Assumptions

Chapter 12. Appendix

12.1. About Us

12.2. Glossary of Terms